Kyverna Therapeutics (KYTX) Strengthens Leadership Team
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/27/2026
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices slide about 2% as US, Iran explore path out of war
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- White House blocks CNN from Air Force One trip, Washington Post reports
- Merck and Daiichi Sankyo withdraw lung cancer drug application
- Exclusive-SK Hynix's Solidigm weighs IPO that could value the unit at up to $150 billion, sources say
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Fox Factory sells Marucci Sports for $225M, cuts debt
Kyverna Therapeutics Strengthens Leadership Team to Accelerate Next Phase of Growth
December 13, 2024 4:05 PM ESTKey Leadership Appointments Bring New Skills and Capabilities to Organization
EMERYVILLE, Calif., Dec. 13, 2024 /PRNewswire/ -- Kyverna Therapeutics, Inc. (Kyverna), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, announced the recent appointments of Dan Maziasz as Chief Business Officer, Cara Bauer as Chief Human Resources Officer, and Tracy Rossin as Senior Vice President of Corporate Affairs, Communications and Investor Relations.Â
... More